The Association Between Radioiodine Refractory in Papillary Thyroid Carcinoma, Sodium/Iodide Symporter Expression, and BRAF V600E Mutation

• Published in: OncoTargets and therapy 2021, Vol.14, p.3959-3969
• Main Authors: Anekpuritanang, Tauangtham, Uataya, Maythad, Claimon, Apichaya, Laokulrath, Natthawadee, Pongsapich, Warut, Pithuksurachai, Paveena
• Format: Article
• Language: English
• ISSN: 1178-6930; 1178-6930
• DOI: 10.2147/OTT.S308910

To study the association between radioiodine refractory papillary thyroid carcinoma, sodium/iodide symporter (NIS) expression, and the mutation. A study was conducted on 30 radioiodine refractory papillary thyroid carcinoma patients and 30 radioiodine-avid papillary thyroid carcinoma patients. The expressions of sodium/iodide symporter and mutated protein were determined by immunohistochemistry using formalin-fixed, paraffin-embedded tissue. The mutated protein was identified in 26 radioiodine refractory papillary thyroid carcinoma subjects (86.7%) and 22 radioiodine-avid papillary thyroid carcinoma subjects (73.3%), with no significant difference between the 2 groups ( = 0.3). Sodium/iodide symporter expression was detected in 4 of 30 cases (13.3%) from the radioiodine-avid papillary thyroid carcinoma group but was negative for all radioiodine refractory cases. There was no association between sodium/iodide symporter expression and radioiodine refractory papillary thyroid carcinoma ( = 0.11). Cases with positive NIS expression were likely negative for mutation (3/4; = 0.02). Papillary thyroid carcinomas with mutation were more likely to be negative for NIS expression. mutation and NIS expressions cannot be used to predict radioiodine sensitivity.